文献速递心境障碍

斯坦福加速智能神经调控治疗难治性抑郁

Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression.
PubMed 文献 · Am J Psychiatry · 2020-04-07

该开放标签研究纳入22例难治性抑郁患者,采用fcMRI引导靶向左侧DLPFC与sgACC抗相关区的加速高剂量iTBS方案(SAINT),5天内每日10次共50次治疗。21例完成者中19例(90.5%)达到缓解标准,意向性分析中19/22例(86.4%)缓解,神经心理测试未见认知副作用。

要点

  • SAINT方案为加速高剂量iTBS,5天50次治疗,fcMRI引导个体化靶向
  • 完成者缓解率90.5%(19/21),意向性分析缓解率86.4%(19/22)
  • 神经心理测试未显示认知副作用,耐受性和安全性良好

核心结论

  • SAINT加速高剂量fcMRI引导iTBS方案治疗难治性抑郁耐受性和安全性良好,缓解率较高,但需双盲假对照试验确认。

研究设计与样本

  • 开放标签研究,纳入22例难治性抑郁患者,采用fcMRI个体化靶向左侧DLPFC与sgACC抗相关区。
  • 50次iTBS会话(每次1800脉冲,间隔50分钟),5天内每日10次,强度为90%静息运动阈值(按皮质深度调整)。

主要发现

  • 1例退出,21例完成;19/21例(90.5%)达到缓解标准(MADRS评分<11)。
  • 意向性分析中19/22例(86.4%)达到缓解标准。
  • 神经心理测试前后对比未发现认知副作用。

关键数值与推荐

  • 缓解标准定义为MADRS评分<11。
  • iTBS参数:每次1800脉冲,50分钟间隔,每日10次,连续5天,强度90%静息运动阈值。

临床怎么用

  • SAINT方案可作为难治性抑郁的潜在加速治疗选择,需个体化fcMRI靶向定位。
  • 临床应用中需关注耐受性和认知功能评估,目前证据限于开放标签研究。

局限性

  • 开放标签设计,无假对照,样本量小(22例),需双盲假对照试验确认缓解率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: New antidepressant treatments are needed that are effective, rapid acting, safe, and tolerable. Intermittent theta-burst stimulation (iTBS) is a noninvasive brain stimulation treatment that has been approved by the U.S. Food and Drug Administration for treatment-resistant depression. Recent methodological advances suggest that the current iTBS protocol might be improved through 1) treating patients with multiple sessions per day at optimally spaced intervals, 2) applying a higher overall pulse dose of stimulation, and 3) precision targeting of the left dorsolateral prefrontal cortex (DLPFC) to subgenual anterior cingulate cortex (sgACC) circuit. The authors examined the feasibility, tolerability, and preliminary efficacy of Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT), an accelerated, high-dose resting-state functional connectivity MRI (fcMRI)-guided iTBS protocol for treatment-resistant depression. METHODS: Twenty-two participants with treatment-resistant depression received open-label SAINT. fcMRI was used to individually target the region of the left DLPFC most anticorrelated with sgACC in each participant. Fifty iTBS sessions (1,800 pulses per session, 50-minute intersession interval) were delivered as 10 daily sessions over 5 consecutive days at 90% resting motor threshold (adjusted for cortical depth). Neuropsychological testing was conducted before and after SAINT. RESULTS: One participant withdrew, leaving a sample size of 21. Nineteen of 21 participants (90.5%) met remission criteria (defined as a score <11 on the Montgomery-Åsberg Depression Rating Scale). In the intent-to-treat analysis, 19 of 22 participants (86.4%) met remission criteria. Neuropsychological testing demonstrated no negative cognitive side effects. CONCLUSIONS: SAINT, an accelerated, high-dose, iTBS protocol with fcMRI-guided targeting, was well tolerated and safe. Double-blinded sham-controlled trials are needed to confirm the remission rate observed in this initial study.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Cole EJ, Stimpson KH, Bentzley BS, et al. Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression. Am J Psychiatry. 2020. PMID: 32252538. doi:10.1176/appi.ajp.2019.19070720

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。